Related by context. All words. (Click for frequent words.) 84 evaluable patients 81 patients evaluable 75 RECIST criteria 73 evaluable subjects 69 partial remissions 69 CR nPR 69 CRp 68 mg kg dose 68 HBeAg positive patients 68 mg BID 68 free survival PFS 68 heavily pretreated 68 prospectively defined 68 Median survival 68 Response Evaluation Criteria 68 CR CRu 68 mg QD 67 RECIST Response Evaluation Criteria 67 undetectable HBV DNA 67 RECIST 67 CCyR 67 biochemical relapse 67 achieved sustained virological 67 achieved ACR# 67 underwent resection 67 progression TTP 67 undetectable HCV RNA 67 dosing cohorts 67 chlorambucil 67 FOLFOX 66 cytogenetic response 66 remission CR 66 mcg albinterferon alfa 2b 66 median PFS 66 heavily pretreated patients 66 mg/m2 dose 66 histologically confirmed 66 n = 66 pegylated interferon alfa 2b 66 #mg QD [002] 66 Solid Tumors criteria 66 prespecified 66 neoadjuvant 65 complete cytogenetic 65 Secondary endpoints include 65 Solid Tumors RECIST 65 Partial Responses 65 tumor shrinkage 65 recurrent glioblastoma multiforme 65 underwent surgical resection 65 prior chemotherapy regimens 65 splenectomized patients 65 REYATAZ r arm 65 randomized #:# 65 dose cohorts 65 endoscopic remission 65 secondary efficacy endpoints 64 neoadjuvant chemotherapy 64 mcg kg 64 Flu Cy 64 metastatic renal cell carcinoma 64 EURIDIS 64 dose escalation phase 64 mRCC 64 recurrent GBM 64 FOLFOX4 64 virologic failure 64 comparator arm 64 stage IIIB 64 complete remissions 64 mCRC patients 64 Kaplan Meier analysis 64 locoregional 64 HBeAg negative patients 64 Secondary endpoints 64 crizotinib PF # 64 mg/m2 64 KRAS mutations occur 63 platinum refractory 63 locoregional disease 63 Secondary endpoints included 63 mg ustekinumab 63 IV NSCLC 63 ribavirin RBV 63 Free Survival PFS 63 #mg/m# [001] 63 placebo dexamethasone 63 MCyR 63 nonresponders 63 plus dexamethasone 63 plus gemcitabine 63 % CI #.#-#.# [003] 63 mcg BID 63 definite stent thrombosis 63 #mg/m# [002] 63 treatment naive genotype 63 systemic ALCL 63 carboplatin paclitaxel 63 resectable 63 cytogenetic responses 63 lymphocytosis 63 HBeAg positive 63 DLTs 63 timepoint 63 oblimersen 63 metastatic RCC 62 FOLFIRI 62 nodular partial response 62 pCR 62 melphalan prednisone 62 dose limiting toxicities 62 dose cohort 62 achieved PASI 62 HCV SPRINT 62 #mg BID [001] 62 achieved CCyR 62 relapsed MM 62 ≥ 62 neoadjuvant therapy 62 HCV RESPOND 2 62 Kaplan Meier estimate 62 estramustine 62 neurologic progression 62 XIENCE V PROMUS Stent 62 #mg BID [002] 62 liver metastases 62 Primary endpoints 62 FOLPI 62 Median PFS 62 decitabine 62 #mg BID [003] 62 primary efficacy endpoint 62 locoregional recurrence 62 plus prednisone 62 squamous histology 62 ACR# response 62 null responders 62 T#I mutation 62 APTIVUS r 62 hematologic 62 pegylated interferon alpha 62 mcg dose 62 chemoradiotherapy 62 Doxil ® 62 achieved sustained virologic 62 composite endpoint 62 HCV genotype 62 methotrexate monotherapy 62 glufosfamide 62 ischemic cardiomyopathy 62 visceral metastases 62 RGT arm 61 unresectable stage 61 CIMZIA TM 61 refractory AML 61 secondary endpoint 61 Pegasys plus Copegus 61 febrile neutropenia 61 ug dose 61 randomized 61 nab paclitaxel 61 treatment emergent adverse 61 viral kinetics 61 sUA 61 GOUT 61 papillary renal cell carcinoma 61 pharmacodynamic 61 treatment naïve genotype 61 biochemical recurrence 61 mg dose 61 pomalidomide 61 cytologically confirmed 61 dacarbazine DTIC 61 primary endpoint 61 unresectable 61 tumor progression TTP 61 relapsed refractory multiple myeloma 61 CLL SLL 61 imatinib therapy 61 receiving highly emetogenic 61 events AEs 61 pT3 61 splenectomized 61 lopinavir r 61 dosing cohort 61 Median progression 61 mg q#h 61 seronegative 61 Partial Response 61 HCV genotype 1 61 Bezielle 61 metastatic GIST 61 mcg QD 61 Fludara 61 severe neutropenia 61 8mg/kg 61 haematologic 61 secondary efficacy endpoint 61 remission induction 61 distant metastasis 61 chemoradiation 61 achieve sustained virologic 61 IIIB NSCLC 61 lamivudine refractory patients 61 cancer mCRC 61 #mg QD [001] 61 leukemia AML 61 μg dose 61 pancreatic adenocarcinoma 61 peginterferon alfa 2b 61 bortezomib refractory 61 azacitidine 60 lopinavir r arm 60 PREZISTA r 60 LEXIVA r 60 secondary endpoints 60 plus methotrexate 60 desvenlafaxine succinate 60 histologically proven 60 ACR Pedi 60 hA# 60 androgen independent 60 recurrent NSCLC 60 posaconazole 60 monotherapy 60 receiving VICTRELIS 60 peg IFN 60 peginterferon alfa 2a #KD 60 adjuvant tamoxifen 60 Folfox 60 tumor lysis syndrome 60 low dose cytarabine 60 stage IIIb IV 60 preoperative chemotherapy 60 BRIM2 60 Aptivus ® 60 Solid Tumors 60 5-FU/LV 60 PEG IFN 60 mg TID 60 refractory NSCLC 60 multicenter Phase 60 lymphopenia 60 cEVR 60 prior relapsers 60 bosentan 60 rituximab refractory 60 HCV infected 60 % CI #.#-#.# [007] 60 ipsilateral breast 60 antiretroviral naïve 60 CMV disease 60 SVR# 60 pT2 60 mg qd 60 pharmacodynamic PD 60 undergone splenectomy 60 TACE 60 advanced adenoma 60 DAS# remission 60 refractory CLL 60 paclitaxel carboplatin 60 plus ribavirin 60 Complete Response CR 60 gemcitabine carboplatin 60 peginterferon 60 EBMT criteria 60 imatinib 60 DLBCL 60 biliary tract cancer 60 MGd 60 histologies 60 CHOP chemotherapy 60 previously untreated follicular 60 HSCT 60 mCi kg 60 metastatic malignant melanoma 60 completely resected 60 PRECiSE 60 KRAS mutations 60 hypercalcemia 60 dacarbazine 60 HBeAg seroconversion 60 ipsilateral stroke 60 tumor regression 60 evaluating REVLIMID 60 HBeAg 60 discontinuations due 60 Pharmacokinetics PK 60 lung metastases 60 infliximab 60 metastatic renal cell 60 vandetanib 60 postintervention 60 complete cytogenetic response 60 events SAEs 60 HER2 positive metastatic breast 60 undetectable virus HCV 59 stage IIIb 59 ribavirin therapy 59 peginterferon alfa 2a 59 NSCLC 59 lymphoma CTCL 59 HCV RNA 59 certolizumab 59 thrombocytopenia 59 gefitinib 59 dasatinib 59 RRMS patients 59 metastatic HRPC 59 underwent CABG 59 follicular lymphomas 59 mutated KRAS 59 relapsed MCL 59 rapid virologic response 59 galiximab 59 relapsed refractory 59 response pCR 59 MVax R 59 virologic breakthrough 59 resected 59 GVAX 59 F FDG PET 59 ACR# responses 59 histologically 59 statistically significant improvement 59 FluCAM arm 59 telaprevir dosed 59 detectable HCV RNA 59 demonstrated antitumor activity 59 Scale EDSS 59 mcg doses 59 Index CDAI 59 adverse cytogenetics 59 TLUS 59 vinorelbine 59 randomized #:#:# 59 R# #mg BID 59 Secondary efficacy endpoints 59 pharmacokinetics PK 59 mapatumumab 59 ALT flares 59 colorectal liver metastases 59 mg administered orally 59 follicular NHL 59 bendamustine 59 sunitinib 59 nonmetastatic 59 castrate resistant 59 mg m² 59 XIENCE V demonstrated 59 TIMP 1 59 FLT3 ITD 59 histologic 59 non splenectomized 59 cilengitide 59 KRAS wild 59 ascending doses 59 mg/m2/day 59 metastatic CRC 59 virological response 59 rFVIIa 59 null responder 59 Taxotere ® 59 antiretroviral naive 59 hematologic adverse 59 T1c 59 breast carcinoma 59 q#d 59 docetaxel prednisone 59 PEGylated interferon beta 1a 59 mitoxantrone 59 MADRS score 59 NMIBC 59 localized renal 59 statistically significant p 59 DAPT 59 plasma uric acid 59 Peg IFN 59 CRu 59 tumor recurrence 59 LVEF 59 PASI scores 59 null responder HCV 59 urinary N telopeptide 59 NATRECOR R 59 alfa 2a 59 VELCADE melphalan 59 ara C 59 octreotide LAR 59 CIMZIA TM certolizumab pegol 59 dose escalation clinical 59 placebo controlled clinical trials 59 ALND 59 sustained virological response 59 CAMMS# 59 μmol L 59 IU ml 59 lymphadenectomy 58 TORISEL 58 thromboembolic events 58 primary endpoints 58 MACCE 58 4mg/kg 58 antiangiogenic therapy 58 virologic 58 PegIFN RBV 58 virologic response 58 timepoints 58 viral kinetic 58 intermittent dosing 58 clodronate 58 huN# DM1 58 CML CP 58 univariate analysis 58 docetaxel 58 IIIA NSCLC 58 distant metastases 58 neoadjuvant treatment 58 sirolimus eluting stents 58 paclitaxel eluting stents 58 Myocardial Infarction Study 58 Xanafide 58 p = NS 58 ACTEMRA TM 58 satraplatin Phase 58 q#h 58 NSABP B 58 XELOX 58 adalimumab 58 EGFR mutation positive 58 statistically significant p = 58 demonstrated statistically significant 58 HGS ETR1 58 nonrandomized 58 microbiologically evaluable 58 IV melanoma 58 randomized blinded 58 receiving INTRON 58 lymphoid malignancies 58 relapsers 58 IFN α 58 saline placebo 58 VcMP 58 apremilast 58 Dacogen injection 58 refractory multiple myeloma 58 highly emetogenic 58 liver transplant recipients 58 relapsed SCLC 58 gemcitabine 58 posttreatment 58 CsA 58 postoperative chemotherapy 58 rituximab 58 naïve HCV 58 P = .# 58 HCV genotypes 58 administered subcutaneously 58 mg RDEA# 58 hepatic metastases 58 pegylated interferon 58 pharmacokinetic PK 58 Psoriasis Area 58 KRAS status 58 tipranavir ritonavir 58 flutamide 58 recurrent VTE 58 curative resection 58 Rate ORR 58 NEVO RES 58 laboratory abnormalities 58 Zometa hazard 58 APPRAISE 58 response CCyR 58 relapsed GBM 58 sirolimus eluting stent 58 REYATAZ r 58 azacytidine 58 confirmed CCyR 58 IMGN# 58 symptomatic BPH 58 genotypic resistance 58 specific antigen PSA 58 hours postdose 58 dose escalation 58 temsirolimus 58 tumor regressions 58 elotuzumab 58 allogeneic stem cell 58 virological failure 58 BR.# 58 metastatic malignant 58 anthracycline containing 58 postoperatively 58 active comparator 58 mg d 58 DMARD 58 angiographic outcomes 58 fosbretabulin 58 nondiabetic patients 58 PSADT 58 pegylated liposomal doxorubicin 58 SAEs 58 cabazitaxel 58 interferon alfa 58 imatinib resistant 58 NLX P# 58 teriflunomide 58 multicenter Phase III 58 TEAEs 58 goserelin 58 efficacy endpoints 58 noninferior 58 docetaxel chemotherapy 58 etanercept 58 stage IIIB IV 58 lymph node metastases 58 LPV r 58 ascending dose 58 TMC# r 58 BCIRG 58 hepatitis C genotype 58 abacavir lamivudine 58 carboplatin 58 cytoreduction 58 BARACLUDE ® 58 oral allopurinol 58 Aflibercept 58 ErbB2 positive 58 clinically meaningful 58 ovarian carcinoma 58 % Confidence Interval 58 NSTE ACS 58 sustained virologic response 58 myeloid metaplasia 57 prostate carcinoma 57 Randomized Phase 57 noninferiority 57 log# 57 5-fluorouracil/leucovorin 57 surrogate endpoint 57 FOLFOX6 57 peripheral blood mononuclear 57 TAXUS Express Stent 57 EFAPROXYN 57 ACR# [002] 57 HIV RNA 57 mycophenolate mofetil 57 Stage IIIb 57 operable breast cancer 57 HER2 negative 57 nucleoside naive 57 phase IIb clinical 57 achieved statistical significance 57 Crohn Disease Activity 57 DAS# CRP 57 castration resistant prostate cancer 57 dose cytarabine 57 multicentre randomized 57 limiting toxicity 57 antibody MAb 57 stage IIIA 57 romiplostim 57 log# copies mL 57 binary restenosis 57 Telintra 57 bortezomib 57 p = #.# [004] 57 randomization 57 microgram kg 57 eosinophilic asthma 57 Amrubicin 57 advanced adenomas 57 pegylated alpha interferon 57 iniparib BSI 57 lymph node involvement 57 adefovir 57 rALLy trial 57 pretransplant 57 elevated ALT 57 adjuvant therapy 57 adjuvant cisplatin 57 adjuvant chemotherapy 57 receptor tyrosine kinase inhibitor 57 small lymphocytic lymphoma 57 multicenter randomized controlled 57 #mg/day [001] 57 adefovir treated 57 dasatinib Sprycel ® 57 vertebral fracture 57 oral rivaroxaban 57 ARB telmisartan 57 pancreatic carcinoma 57 debulking surgery 57 log# reduction 57 mitoxantrone plus 57 underwent liver transplantation 57 taxane resistant 57 thromboembolic 57 CC genotype 57 SinuNase TM 57 thrombocytopenic 57 clinically meaningful improvement 57 seroprotection 57 moderately emetogenic 57 leukopenia 57 median survivals 57 Phase 2b study 57 FOLFIRI alone 57 trials RCTs 57 ABC/3TC 57 cisplatin gemcitabine 57 clinically meaningful differences 57 mg m 57 disease progression TTP 57 FOLFOX4 alone 57 pegylated interferon peg IFN 57 PSA nadir 57 CANCIDAS 57 HBeAg negative 57 Baseline characteristics 57 HORIZONS AMI trial 57 Kaplan Meier estimates 57 DOXIL 57 radiotherapy RT 57 EGFR TKI 57 mg kg 57 % CI #.#-#.# [005] 57 VFEND 57 transplant ASCT 57 epithelial tumors 57 HIV uninfected 57 Thrombolysis 57 dose regimens 57 TAXUS ATLAS 57 sirolimus stent 57 alemtuzumab treated 57 posttransplant 57 aged ≥ 57 ZACTIMA 57 HRPC 57 refractory acute myeloid 57 radical nephrectomy 57 ispinesib administered 57 pertuzumab 57 atazanavir ritonavir 57 coronary revascularization 57 cGy 57 low dose dexamethasone 57 EGFR mutations 57 placebo 57 HGPIN 57 undetectable viral load 57 Allovectin 7 ® 57 taxane therapy 57 resected pancreatic cancer 57 VGPR 57 interferon alfa 2a 57 cisplatin vinorelbine 57 dose dexamethasone 57 fallopian tube cancers 57 anterior uveitis 57 GLIADEL R Wafer 57 mucosal healing 57 p = #.# [002] 57 primary efficacy endpoints 57 gemcitabine Gemzar ® 57 elevated LDH 57 hepatocellular carcinomas 57 standard chemotherapy regimen 57 nephrectomy 57 HLA DR2 57 VT VF 57 PREZISTA rtv 57 sarcomatoid 57 BEACOPP 57 Pharmacokinetic parameters 57 mg/m2 cohort 57 TNF antagonist 57 piperacillin tazobactam 57 cytogenic 57 hepatectomy 57 metastatic pancreatic 57 TMC# C# 57 β blockers 57 hematologic toxicity 57 ZYBRESTAT 57 ASCT 57 preintervention 57 refractory metastatic 57 BENICAR HCT 57 Diffuse Large B 57 thymoma 57 TAXOTERE R 57 HES CEL 57 randomized multicenter trial 57 mcg Albuferon 57 genotype 1a 57 telaprevir dosing 57 nodal metastases 57 nonfatal MI 57 unstable angina UA 57 unresectable HCC 57 PREZISTA r arm 57 intravesical 57 trastuzumab 57 paclitaxel cisplatin 57 FLT3 mutations 57 recurrent malignant glioma 56 docetaxel Taxotere ® 56 prostate cancer CaP 56 Tarceva TM 56 unfractionated heparin UFH 56 nilotinib 56 mITT 56 unresectable tumors 56 Hodgkin lymphoma HL 56 ACR# ACR# 56 tipranavir r 56 CTEPH 56 docetaxel pretreated 56 lamivudine monotherapy 56 concurrent chemoradiation 56 HER2 expression 56 â ‰ ¥ 56 lanthanum carbonate 56 cystectomy 56 RECORD1 56 systemically administered 56 demonstrated clinically meaningful 56 Phase 1b 56 epithelial ovarian 56 AVOREN 56 doxorubicin cyclophosphamide 56 adjunctive placebo 56 mg kg cohorts 56 randomized Phase 2b 56 patients undergoing CABG 56 Phase 2a trial 56 TNF antagonists 56 cell lymphoma CTCL 56 intraocular inflammation 56 TELCYTA 56 fallopian tube carcinoma 56 unfavorable prognostic 56 serum antibody 56 allogeneic SCT 56 oral ridaforolimus 56 Solid Tumours 56 IIa trial 56 ertapenem 56 Virologic 56 superficial bladder cancer 56 lumbar spine BMD 56 FluCAM 56 Traficet EN 56 trabectedin 56 lenalidomide Revlimid R 56 multiple myeloma MM 56 neutropenia dehydration dyspnea 56 oral FTY# 56 huC# DM4 56 liver histology 56 seroconversion 56 neratinib 56 virologic responses 56 octreotide 56 nadolol 56 primary patency 56 Elitek 56 metastatic castration resistant 56 Follicular Lymphoma 56 Pegasys ® 56 fludarabine 56 fibrinolytic therapy 56 discontinuations 56 anthracyclines taxanes 56 invasive carcinomas 56 bladder carcinoma 56 axillary lymph node 56 Ph + ALL 56 fluorouracil 56 EBRT 56 Newly Diagnosed Multiple Myeloma 56 aspartate aminotransferase AST 56 sipuleucel T 56 mg kg BID 56 efficacy endpoint 56 phase IIb study 56 ADHF 56 mcg linaclotide 56 postmenopausal osteoporotic women 56 FDG-PET/CT 56 μg kg 56 severe oral mucositis 56 assessing T DM1 56 castrate resistant prostate cancer 56 rindopepimut 56 velafermin 56 dapagliflozin plus 56 esophageal carcinoma 56 xenograft models 56 REVIVE Diabetes 56 NEVO ™ 56 serum HCV RNA 56 infliximab monotherapy 56 fluoropyrimidine 56 SPIRIT FIRST 56 doxorubicin docetaxel 56 PREZISTA ritonavir 56 epithelial ovarian cancer 56 prospective multicenter 56 μg doses 56 prospectively stratified 56 ng dL 56 relapsing multiple sclerosis 56 LHRH receptor positive 56 -#.# log# 56 KRAS mutant tumors 56 diagnosed GBM 56 nonmetastatic prostate cancer 56 forodesine 56 ongoing Phase 1b 56 LibiGel Phase III 56 mITT population 56 alanine transaminase ALT 56 Phase Ib II 56 copies mL 56 seropositive patients 56 pegylated interferon alfa 2a 56 chemoradiation therapy 56 clinically meaningful improvements 56 basal cell carcinoma BCC 56 confidence interval CI 56 pheochromocytoma 56 mg/m2 administered 56 VICTRELIS 56 anemia hemoglobin 56 autoantibody positive 56 evaluating tivozanib 56 mcg kg REBETOL 56 adjuvant GIST 56 parathyroidectomy 56 NovoTTF 56 liver resection 56 acute coronary syndromes ACS 56 placebo p = 56 relapsed AML 56 TDF FTC 56 serum phosphorus 56 tumor necrosis 56 K ras mutations 56 phase Ib 56 elagolix 56 ATACAND 56 myeloablative 56 Epratuzumab 56 retrospective cohort 56 nonoperative treatment 56 Q2W 56 ancrod 56 ARCOXIA 56 oral diclofenac 56 medically inoperable 56 CYPHER Stent 56 QTc prolongation 56 EDSS scores 56 severe hypoglycemic 56 blinded randomized placebo controlled 56 concomitant antibiotics 56 VP# [004] 56 serum urate 56 AIR CF1 56 Timed Walk 56 QTcF 56 cisplatin chemotherapy 56 peg interferon 56 INC# 56 pericardial effusion 56 CTAP# Capsules 56 IV metastatic melanoma 56 IL#B 56 Phase #/#a 56 androgen suppression 56 TAXUS Stent 56 tapentadol ER 56 COPEGUS 56 % CI #.#-#.# [006] 56 rosuvastatin #mg 56 anti EGFR antibody 56 topotecan 56 hemodynamically significant 56 receiving golimumab 56 adjuvant radiotherapy 56 PNH patients 56 resistant ovarian cancer 56 trastuzumab Herceptin R 56 YERVOY 56 peripheral sensory neuropathy 56 NYHA Class II 56 #Gy 56 tanespimycin 56 everolimus eluting stents 56 nutlin 3a 56 androgen deprivation 56 mCRPC 56 ixabepilone 56 amrubicin 56 ponatinib 56 metastatic hormone refractory 56 macroalbuminuria 56 tirofiban 56 HUMIRA achieved PASI 56 stent thromboses 56 baseline HbA1c 56 leukemia CLL 56 oxycodone CR 56 CIMZIA ™ 56 advanced hepatocellular carcinoma 56 TURBT 56 Toxicities 56 adriamycin 56 MabCampath 56 TRANSFORMS 56 SCH # 56 histological subtype 56 papillary thyroid carcinoma 56 CLARITY study 56 target vessel revascularization 56 peginterferon alfa 56 #mg/kg [002] 56 intravenous bolus 55 relapsed Hodgkin lymphoma 55 retreatment 55 molecular remissions 55 pharmacokinetic PK study 55 QTc 55 tumor histology 55 zalutumumab 55 primary hypercholesterolemia 55 Xelox 55 intracranial hemorrhage ICH 55 iodixanol 55 interferon alfa 2b 55 ACTEMRA 55 CYT# potent vascular disrupting 55 antithymocyte globulin 55 interquartile range 55 Phase #/#a trial 55 specified primary endpoint 55 pimecrolimus cream 55 Engerix B 55 median CD4 55 Ophena TM 55 Phase Ib clinical 55 chronic GVHD 55 underwent radical prostatectomy 55 lispro 55 imetelstat 55 ANCHOR trial 55 dexamethasone 55 lumiliximab 55 renal cell carcinomas 55 axitinib 55 reinfarction 55 PROSTVAC VF 55 GnRH agonist 55 Events MACE 55 relapsed multiple myeloma 55 Pegylated Interferon 55 SUTENT 55 IIIa inhibitor 55 calcineurin inhibitor 55 #mg dose [002] 55 SABCS 55 HIV HCV coinfected 55 hyperoxaluria 55 NCT# ClinicalTrials.gov 55 receiving ISENTRESS 55 unstable angina pectoris 55 tolerated dose MTD 55 ALT normalization 55 nonsmall cell lung cancer 55 fluvastatin 55 PegIFN 55 intravesical therapy 55 Pivotal Phase III 55 chronic HCV genotype 55 relapsed CLL 55 nonoperative 55 RE LY ® 55 NEUVENGE 55 weekly intravenous infusions 55 intradermal injections 55 irinotecan chemotherapy 55 mesalamine granules 55 BRIM3 55 double blinded placebo